Parkinson’s Disease Medication Stocklist, Acute Hospitals (213)

Warning

exp date isn't null, but text field is

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments. Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics.

Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

Introduction

This guidance highlights the importance of continuing Parkinson’s disease (PD) medication and provides details of the location of PD medications across NHSGGC which can be accessed for immediate supply.

Assessment / monitoring

It is CRUCIAL NOT TO STOP PD DRUGS for any significant length of time ie > 2 hours or to miss any doses i.e. as there is a risk of Neuroleptic Malignant-Like Syndrome (Parkinson hyperpyrexia syndrome, PHS) which may be fatal. Symptoms include rigidity, pyrexia, and reduced conscious level. There may be features of autonomic instability, and serum creatine kinase (CK) may be elevated. Complications of PHS include acute renal failure, aspiration pneumonia, deep venous thrombosis / pulmonary embolism, and disseminated intravascular coagulation.

General management

Where a patient does not have an individual supply of their PD medicine, access supplies via the pharmacy or the local main holding areas of PD medications across NHSGGC (see table 1). It is important for PD medications to be administered at exact times. This should be clearly annotated on the prescription chart.

Table 1: Location of PD medicines across acute hospital sites

 

PD drug

NVH

QEUH

GRI

GGH

RAH

IRH

VoL

Amantadine 100mg CAPs

x

55, EDC

x

x

x

x

14

Amantadine 50mg/5ml liquid

x

55, EDC

x

x

x

x

x

Apomorphine 10mg/ml(5ml amp)

x

EDC

EDC

x

3

x

x

Apomorphine pre-filled syringe 5mg/ml(10ml)

x

55, EDC

EDC

x

3

EDC

x

Bromocriptine 2.5mg TABs

x

EDC

x

x

x

x

14

Co-beneldopa 12.5/50 CAPs

NVH1&2

67,55, EDC

39

EDC

EDC

AMU, 3

GSouth, 2,3, EDC

 

14

Co-beneldopa 12.5/50 DISP

NVH1

67,55, EDC

39

EDC

3,36

2, EDC, J North

14

Co-beneldopa 25/100 CAPs

NVH2

67,55, EDC

39

EDC

3

2,3

14

Co-beneldopa 25/100 DISP

NVH2

55

39

EDC

3

2

14

Co-beneldopa 50/200 CAPs

x

55

x

x

x

2

14

Co-beneldopa 25/100 mr CAPs

NVH1&2

55, EDC

39

x

3

2

14

Co-careldopa 10/100 TABs

x

55

39

EDC

x

EDC

14

Co-careldopa 12.5/50 TABs

NVH1&2

67,55, EDC

39

EDC

3

GSouth,2, EDC

14

Co-careldopa 25/100 TABs

NVH1 &2

67,55, EDC

39

EDC

3

2,3

14

Co-careldopa 25/250 TABs

x

55,EDC

39

x

x

EDC

14

Co-careldopa 25/100 mr TABs

NVH1&2

55, EDC

39

x

3

EDC

14

Co-careldopa 50/200 mr TABs

NVH1&2

55

x

x

3

x

14

Entacapone 200mg TABs

NVH1

55, EDC

39

x

3

EDC

14

Pramipexole 88mcg TABs

x

55

39

x

3

EDC, 2

14

Pramipexole 180 mcg TABs

x

55

39

x

3

EDC

14

Pramipexole 350 mcg TABs

x

EDC

39

x

x

x

x

Pramipexole 700 mcg TABs

x

x

x

x

3

EDC

14

Pramipexole 1050 mcg mr TABs

x

55

x

x

x

2

x

Pramipexole 1570 mcg mr TABs

x

55

x

x

x

2

x

Pramipexole 2100mcg mr TABs

x

55

x

x

x

2

x

Pramipexole 2.62mg mr TABs

x

55, EDC

x

x

x

2

14

Rasagiline* 1mg TABs

x

55

39

x

x

x

x

Ropinirole 250 mcg TABs

x

55, EDC

39

x

x

x

14

Ropinirole 1mg TABs

x

EDC

39

x

3

EDC

14

Ropinirole 2mg TABs

x

x

x

x

3

2

14

Ropinirole 2mg m/r TABs

x

55, EDC

39

x

3

EDC, 2

14

Ropinirole 4mg m/r TABs

x

55

x

x

x

2

14

Ropinirole 8mg m/r Tabs

x

55, EDC

x

x

x

2

14

Rotigotine 2mg/24 hr patch

NVH1

55, EDC

39

EDC

3

EDC, 2, J North

14

Rotigotine 4mg/24hr patch

NVH1

55

39

EDC

3

EDC, 2

14

Rotigotine 6mg/24hr patch

x

55

x

x

3

2

14

Rotigotine 8mg/24hr patch

x

55

x

x

3

2

x

Selegiline 5mg TABs

x

55

39

x

3

EDC

14

Stanek 50/12.5/200 TABs

x

55, EDC

39

EDC

3

EDC, 2

14

Stanek 75/18.75/200 TABs

x

55, EDC

39

EDC

3

EDC, 2

14

Stanek 100/25/200 TABs

x

55, EDC

39

EDC

3

EDC, 2

14

Stanek 125/31.25/200 TABs

x

55, EDC

39

EDC

3

EDC, 2

14

Stanek 150/37.5/200 TABs

x

55, EDC

39

EDC

3

EDC

14

Stanek 175/43.75/200 TABs

x

55

x

x

x

EDC, 2

14

Stanek 200/50/200 TABs

x

55

39

x

x

EDC,2

14

 

  • *Rasagiline is non-formulary, however it can be supplied to patients established on therapy. Request for new initiation would need to follow GGC non-formulary
  • Duodopa intestinal gel – Patient’s own supply would need to be brought into hospital for
  • x -not available on ward (contact pharmacy/on-call pharmacist for a supply)

 

NVH-New Victoria Hospital

QEUH-The Queen Elizabeth University Hospital

GRI-Glasgow Royal Infirmary

GGH-Gartnavel General Hospital

RAH-Royal Alexandra Hospital

IRH-Inverclyde Royal Hospital

VoL-Vale of Leven

 

EDC-Emergency Drug Cupboard

ARU-Acute Receiving Unit

AMU - Acute Medical unit

 

PLEASE NOTE: Further stock of PD medications is kept at pharmacies across NHSGGC sites. Contact pharmacy / on-call pharmacist for a supply.

 

Last reviewed: 04 November 2019

Next review: 04 November 2022

Author(s): Yasmin Al-Din

Version: 7

Author Email(s): [email protected]

Approved By: GGC Parkinson's Excellence Group

Document Id: 213